$INO News

Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3

Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ...

Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

Inovio Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript

Inovio Pharmaceuticals Q2 EPS $(0.07) Beats $(0.22) Estimate

INOVIO to Report Second Quarter Financial Results on August 12, 2026

Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

INOVIO Announces Pricing of $20.0 Million Public Offering

INOVIO Announces Proposed Public Offering

INOVIO Pharmaceuticals Announces Proposed Public Offering Of Shares And Warrants

Inovio Pharmaceuticals May Offer Up To $300 Mln Of Securities

Inovio Pharmaceuticals, Inc. (INO) Presents at Jefferies Global Healthcare Conference 2026 Transcript

HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

INOVIO to Participate in Upcoming Scientific and Investor Conferences

INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial

Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China

Inovio Pharmaceuticals' Partner For VGX-3100 In China, ApolloBio, Announces Topline Results From Its Pivotal Phase 3 Trial Of VGX-3100; Trial Met Its Predefined Primary Efficacy Endpoint And Demonstrated An Overall Favorable Safety And Tolerability Profile

Inovio Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation